AUGA group, AB financials
AUGA group, AB
Country: LT Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
48510000P2S3LHJPX414 Financial statements
(EUR, as reported — unscaled; 115 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €51.5M | €55.3M |
| Cost of sales | €40.2M | €49.5M |
| Gross profit | €5.4M | -€4.9M |
| Other income | €1.1M | €250.0K |
| Administrative expenses | €8.3M | €9.4M |
| Operating profit (EBIT) | -€2.6M | -€21.1M |
| Finance costs | €7.1M | €11.4M |
| Profit before tax | -€10.4M | -€32.4M |
| Income tax expense | €265.0K | €55.0K |
| Profit for the year | -€10.7M | -€32.4M |
| — attributable to owners | -€10.6M | -€32.4M |
| — attributable to NCI | -€68.0K | -€76.0K |
| Total comprehensive income | -€11.2M | -€32.1M |
| Per share | ||
| Diluted EPS | €-0.05 | €-0.14 |
| Free cash flow / share | €0.01 | €0.01 |
| Cash flow statement | ||
| Cash generated from operations | €8.6M | €13.5M |
| Net cash from operating activities | €3.2M | €5.6M |
| Net cash from investing activities | -€624.0K | -€3.7M |
| Purchase of PP&E (capex) | €594.0K | €3.6M |
| Purchase of intangibles | €0 | €1.2M |
| Net cash from financing activities | -€3.7M | -€3.6M |
| Proceeds from borrowings | €0 | €1.2M |
| Repayments of borrowings | €1.6M | €3.8M |
| Lease liability payments | €7.2M | €5.9M |
| Balance sheet | ||
| Total assets | €184.8M | €203.1M |
| Non-current assets | €113.8M | €153.1M |
| Property, plant & equipment | €59.3M | €89.0M |
| Right-of-use assets | €36.3M | €45.3M |
| Intangible assets & goodwill | €25.0K | €161.0K |
| Current assets | €36.0M | €50.0M |
| Inventories | €12.4M | €17.0M |
| Trade & other receivables | €5.9M | €7.6M |
| Cash & equivalents | €668.0K | €1.7M |
| Total equity | €19.5M | €30.3M |
| — attributable to owners | €19.3M | €29.9M |
| Non-controlling interests | €250.0K | €318.0K |
| Non-current liabilities | €67.4M | €46.0M |
| Long-term borrowings | €23.5M | €0 |
| Lease liabilities (non-current) | €31.2M | €39.1M |
| Current liabilities | €82.0M | €126.8M |
| Short-term borrowings | €57.3M | €83.6M |
| Lease liabilities (current) | €7.9M | €9.1M |
| Trade & other payables | €8.8M | €26.0M |
| Deferred tax liabilities | €2.8M | €2.7M |
| Derived metrics | ||
| Free cash flow | €2.6M | €2.0M |
| Operating margin | -5.1% | -38.1% |
| Net margin | -20.8% | -58.7% |
| Return on equity | -54.8% | -107.2% |
| Cash conversion ratio | -0.30× | -0.17× |
| Capex coverage | 5.46× | 1.57× |
| Other reported items | ||
| Adjustments For Amortisation Expense | €25.0K | €83.0K |
| Adjustments For Decrease Increase In Biological Assets | -€1.1M | -€11.7M |
| Adjustments For Decrease Increase In Inventories | -€2.1M | €10.5M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€898.0K | €2.8M |
| Adjustments For Depreciation Expense | €5.2M | €7.5M |
| Adjustments For Dividend Income | €0 | €0 |
| Adjustments For Finance Costs | €0 | €0 |
| Adjustments For Gains Losses On Change In Fair Value Less Costs To Sell Biological Assets | €5.9M | €10.8M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Inventories | -€20.0K | €30.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Trade and Other Receivables | €179.0K | €686.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -€3.2M | €1.0M |
| Adjustments For Interest Income | €0 | €29.0K |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -€30.0K | -€985.0K |
| Adjustments For Sharebased Payments | €469.0K | €607.0K |
| Cash Advances and Loans Made To Other Parties Classified As Investing Activities | €0 | €0 |
| Cash Receipts From Repayment of Advances and Loans Made To Other Parties Classified As Investing Activities | €0 | €0 |
| Comprehensive Income Attributable To Noncontrolling Interests | -€68.0K | -€76.0K |
| Comprehensive Income Attributable To Owners of Parent | -€11.1M | -€32.1M |
| Current Biological Assets | €14.8M | €20.7M |
| Deferred Tax Assets | €2.7M | €2.9M |
| Depreciation Rightofuse Assets | €6.8M | €8.0M |
| Dividends Received Classified As Investing Activities | €0 | €0 |
| Equity and Liabilities | €184.8M | €203.1M |
| Gains Losses On Initial Recognition of Biological Assets For Current Period | -€5.9M | -€10.8M |
| Income Tax Relating To Changes In Revaluation Surplus of Other Comprehensive Income | -€68.0K | €80.0K |
| Increase Decrease In Cash and Cash Equivalents | -€1.1M | -€1.7M |
| Increase Decrease Through Sharebased Payment Transactions | €469.0K | €607.0K |
| Increase Decrease Through Transfers and Other Changes Equity | €0 | €0 |
| Interest Paid Classified As Operating Activities | €5.4M | €7.9M |
| Inventory Writedown2011 | €2.2M | €1.2M |
| Investment Accounted For Using Equity Method | €57.0K | €57.0K |
| Investments In Subsidiaries | €0 | €0 |
| Issue of Equity | €0 | €0 |
| Issued Capital | €67.8M | €67.8M |
| Liabilities | €165.3M | €172.8M |
| Liabilities Included In Disposal Groups Classified As Held For Sale | €15.8M | €0 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | €35.0M | €0 |
| Noncurrent Biological Assets | €15.0M | €14.0M |
| Noncurrent Government Grants | €3.6M | €4.2M |
| Noncurrent Receivables | €0 | €0 |
| Other Adjustments For Noncash Items | €0 | €0 |
| Other Adjustments To Reconcile Profit Loss | €572.0K | €0 |
| Other Cash Payments To Acquire Equity Or Debt Instruments of Other Entities Classified As Investing Activities | €0 | €0 |
| Other Comprehensive Income | -€465.0K | €295.0K |
| Other Comprehensive Income Before Tax Gains Losses On Revaluation | -€402.0K | €501.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Revaluation | -€465.0K | €295.0K |
| Other Current Assets | €2.2M | €2.9M |
| Other Current Liabilities | €8.1M | €8.2M |
| Other Gains Losses | €74.0K | €481.0K |
| Other Inflows Outflows of Cash Classified As Operating Activities | €13.0K | €5.6M |
| Other Noncurrent Assets | €419.0K | €1.7M |
| Other Noncurrent Liabilities | €6.4M | €0 |
| Proceeds From Government Grants Classified As Investing Activities | €0 | €0 |
| Proceeds From Issue of Bonds Notes and Debentures | -€63.0K | €5.0M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | -€30.0K | €985.0K |
| Profit Loss From Continuing Operations | -€10.0M | -€32.6M |
| Profit Loss From Discontinued Operations | -€725.0K | €117.0K |
| Reserve of Sharebased Payments | €2.7M | €2.7M |
| Retained Earnings | -€66.6M | -€65.2M |
| Revaluation Surplus | €15.4M | €15.9M |
| Revenue From Dividends | €0 | €0 |
| Selling Expense | €798.0K | €1.2M |
| Share Premium | €0 | €6.7M |
| Statutory Reserve | €0 | €2.0M |
| Tax Effect From Change In Tax Rate | €131.0K | €126.0K |
Methodology
Every line item above is a fact tagged in AUGA group, AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.